[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2623713A1 - Composition pharmaceutique destinee au traitement de troubles gastro-intestinaux - Google Patents

Composition pharmaceutique destinee au traitement de troubles gastro-intestinaux Download PDF

Info

Publication number
FR2623713A1
FR2623713A1 FR8815444A FR8815444A FR2623713A1 FR 2623713 A1 FR2623713 A1 FR 2623713A1 FR 8815444 A FR8815444 A FR 8815444A FR 8815444 A FR8815444 A FR 8815444A FR 2623713 A1 FR2623713 A1 FR 2623713A1
Authority
FR
France
Prior art keywords
methyl
compound
salt
physiologically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR8815444A
Other languages
English (en)
French (fr)
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FR2623713A1 publication Critical patent/FR2623713A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR8815444A 1987-11-26 1988-11-25 Composition pharmaceutique destinee au traitement de troubles gastro-intestinaux Withdrawn FR2623713A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878727685A GB8727685D0 (en) 1987-11-26 1987-11-26 Medicaments

Publications (1)

Publication Number Publication Date
FR2623713A1 true FR2623713A1 (fr) 1989-06-02

Family

ID=10627570

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8815444A Withdrawn FR2623713A1 (fr) 1987-11-26 1988-11-25 Composition pharmaceutique destinee au traitement de troubles gastro-intestinaux

Country Status (6)

Country Link
JP (1) JPH01250319A (ja)
DE (1) DE3839883A1 (ja)
FR (1) FR2623713A1 (ja)
GB (2) GB8727685D0 (ja)
IT (1) IT1235158B (ja)
NL (1) NL8802906A (ja)

Also Published As

Publication number Publication date
DE3839883A1 (de) 1989-06-08
IT8848597A0 (it) 1988-11-25
GB8827641D0 (en) 1988-12-29
NL8802906A (nl) 1989-06-16
GB2212724A (en) 1989-08-02
GB8727685D0 (en) 1987-12-31
IT1235158B (it) 1992-06-22
JPH01250319A (ja) 1989-10-05

Similar Documents

Publication Publication Date Title
FR2613934A1 (fr) Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament
KR100357650B1 (ko) 신경계 장애를 치료하기 위한 헤테로사이클릭 비닐에테르
CN1805938B (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
BE1001004A4 (fr) Nouvelles cetones tricycliques utiles comme medicaments, procede et intermediaires pour leur preparation.
FR2758723A1 (fr) Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
CH664152A5 (fr) Derives de tetrahydrocarbazolones.
EP2212284B1 (en) Calcium receptor modulating agents
WO2004022544A1 (fr) Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
CH642635A5 (fr) Derives de l'imidazole, procedes pour leur preparation et compositions medicamenteuses contenant ces derives.
US4835173A (en) Method of medical treatment
CA2575059A1 (en) Pharmaceutical compositions comprising cilobradine
EP0655248B1 (fr) Utilisation des dérivés de 1- 4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl 1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique
WO2003082256A2 (fr) Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1
EP1173179A2 (fr) Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles depressifs majeurs
CH679553A5 (ja)
CH678149A5 (ja)
BE1009060A3 (fr) Compositions pharmaceutiques et procede permettant leur preparation.
FR2623713A1 (fr) Composition pharmaceutique destinee au traitement de troubles gastro-intestinaux
JPH01316319A (ja) 医薬
CH674008A5 (ja)
FR2705569A1 (fr) Composition pharmaceutique à base d'une imidazolylcarbazolone destinée à l'administration rectale.
JPS63211227A (ja) 医薬
IL95245A (en) Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and
EP0626372A1 (fr) 2-Hydroxy-3-(1-(1H-imidazol-4-yl)alkyl)-benzènecarboximidamides pour le traitement du glaucome
EP1171133B1 (en) R-hydroxynefazodone

Legal Events

Date Code Title Description
ST Notification of lapse